Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

Mario Tiribelli, Roberto Latagliata, Luigiana Luciano, Fausto Castagnetti, Antonella Gozzini, Giovanna Rege Cambrin, Mario Annunziata, Fabio Stagno, Patrizia Pregno, Francesco Albano, Elisabetta Abruzzese, Pellegrino Musto, Enrico Montefusco, Carmen Fava, Renato Fanin, Fabrizio Pane, Gianantonio Rosti, Massimo Breccia, Giuliana Alimena, Paolo Vigneri

Research output: Contribution to journalArticlepeer-review

Abstract

To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalAnnals of Hematology
Volume92
Issue number2
DOIs
Publication statusPublished - Jan 2013

Keywords

  • BCR-ABL mutations
  • CML
  • Dasatinib
  • Elderly patients
  • Imatinib resistance

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this